Table 2.

Clinical features of the patient cohort

UPMC (n = 14)RPCI (n = 19)FCCC (n = 8)Mich (n = 26)
Age at dx60.3 ± 10.572.4 ± 7.356.1 ± 7.758.9 ± 15.9
Primary/Recur samples14/017/25/326/0
Grade
 Low2013
 High1219723
Stage
 Early (1–2)1032
 Late (3–4)1319524
Histology
 Serous1017515
 Clear cell0101
 Endometrioid1031
Other3109
Pre-rx CA-125a (# censored)340.2 ± 544.0 (5)392.4 ± 646.0 (1)463.3 ± 785.0 (4)105.0 ± 143.4 (0)
Endo rx
 Tamoxifen1118714
 AI2016
 Both2106
Days on endo rx351 ± 358419 ± 661168 ± 115260 ± 310
 Min38223130
 Max90828503961,470
Survival after endo rx (days)882 ± 564717 ± 880738 ± 653834 ± 774
Overall survival (days)2,346 ±1,3022,019 ± 1,3722,129±1,1041,880 ± 1,228
  • Abbreviations: dx, diagnosis; FCCC, Fox Chase Cancer Center; Mich, The University of Michigan; RPCI, Roswell Park Cancer Institute; rx, treatment; UPMC, University of Pittsburgh Medical Center.

  • aPre- and post-endocrine therapy CA-125 was available for 45 patients.